ATCell

American CryoStem Corporation · Phase 1 active Biologic

At a glance

Generic name	ATCell
Also known as	Autologous Adipose Derived Mesenchymal Stem Cells
Sponsor	American CryoStem Corporation
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection (PHASE1)
ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ATCell CI brief — competitive landscape report
ATCell updates RSS · CI watch RSS
American CryoStem Corporation portfolio CI